Abstract
Importance While COVID-19 vaccines are highly effective against disease, breakthrough infections may occur in the context of rising variants of concern.
Objective We paired random and passive surveillance nucleic acid testing with analysis of viral whole genomic sequences to detect and describe breakthrough infections, focusing in a university community.
Design Anterior nasal swabs were collected from individuals for a nucleic acid amplification test (NAAT) for detection of SARS-CoV-2. A subset of NAAT positive samples was sequenced to determine variants associated with infections. Included in the testing and sequencing protocol were individuals that were fully vaccinated.
Setting This study was performed as part of a surveillance program for SARS-CoV-2 on a university campus with 49,700 students and employees.
Participants Surveillance testing was random and included approximately 10% of the population each week. Additionally, individuals self-identified with COVID-19 related symptoms or those that had close contact with SARS-CoV-2 positive individuals were also tested.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was in part funded by support to G.C. from the Purdue Department of Biological Sciences.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data were obtained in deidentified format from the electronic health record system from One-to-One Health. Approval from the One-to-One Health review board was obtained. The Institutional Review Board from the Purdue University Human Research Protection Program determined that viral genome sequencing of deidentified remnant RNA samples included in this study is not research involving human subjects (IRB-2021-438)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Genomic data are available on GISAID (see Table 1 for accession numbers).
